Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

In clinical practice, there is a sense of urgency to address motor neuron loss in SMA from the earliest sign or even prior to symptoms, to prevent additional disease progression,” said ... positive results across two clinical trials of different ages

Latest news

More from news
Approximately 1 fully matching, plus 304 partially matching documents found.

Latest Intelligence

  • The search for effective drug treatments for COVID-19 The search for effective drug treatments for COVID-19

    NIAID’s Adaptive COVID-19 Treatment Trial (ACTT-1) showed that remdesivir Standard of Care (SOC) significantly shortened time to recovery, provided greater clinical improvement and also reduced disease progression compared ... improvement and also

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    While there are medications that can address some of the risk factors for CKD, no cure currently exists, and few current therapies work directly to slow renal disease progression. ... At AstraZeneca, we are working to advance solutions across the full

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    Despite the significant anecdotal evidence, an initial study of Kaletra in China demonstrated some disappointing results; it did not seem to have any significant effect on disease progression. ... Infectious disease expert Lindsey R Braden and NEJM editor

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... If people are hoping for any of the molecules under investigation to be a

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    According to the study, the blood test is able to identify this protein 20 years before the symptoms of the disease start to present. ... Alzheimer’s R&D has had to diversify as companies and researchers become increasingly aware that the disease has a

More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics